BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Feuerecker B, Heimer MM, Geyer T, Fabritius MP, Gu S, Schachtner B, Beyer L, Ricke J, Gatidis S, Ingrisch M, Cyran CC. Artificial Intelligence in Oncological Hybrid Imaging. Rofo 2022. [PMID: 36170852 DOI: 10.1055/a-1909-7013] [Reference Citation Analysis]
2 Urso L, Panareo S, Castello A, Ambrosio MR, Zatelli MC, Caracciolo M, Tonini E, Valpiani G, Boschi A, Uccelli L, Cittanti C, Bartolomei M. Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics 2022;14:2009. [DOI: 10.3390/pharmaceutics14102009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules 2022;27:5231. [DOI: 10.3390/molecules27165231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Opalińska M, Morawiec-sławek K, Kania-kuc A, Al Maraih I, Sowa-staszczak A, Hubalewska-dydejczyk A. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022;13:929391. [DOI: 10.3389/fendo.2022.929391] [Reference Citation Analysis]
5 Simón M, Jørgensen JT, Khare HA, Christensen C, Nielsen CH, Kjaer A. Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model. Pharmaceutics 2022;14:1284. [PMID: 35745856 DOI: 10.3390/pharmaceutics14061284] [Reference Citation Analysis]
6 Elliyanti A. Radiopharmaceuticals in Modern Cancer Therapy. Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy 2022. [DOI: 10.5772/intechopen.99334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Laudicella R, Comelli A, Liberini V, Vento A, Stefano A, Spataro A, Crocè L, Baldari S, Bambaci M, Deandreis D, Arico’ D, Ippolito M, Gaeta M, Alongi P, Minutoli F, Burger IA, Baldari S. [68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The “Theragnomics” Concept. Cancers 2022;14:984. [DOI: 10.3390/cancers14040984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, O'Dorisio T, O'Dorisio MS, Wild D, Christ E, Nicolas GP. Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. Cancers (Basel) 2021;13:6290. [PMID: 34944910 DOI: 10.3390/cancers13246290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wehrend J, Silosky M, Xing F, Chin BB. Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network. EJNMMI Res 2021;11:98. [PMID: 34601660 DOI: 10.1186/s13550-021-00839-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Bodei L, Kidd M, Modlin I. Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management. Current Opinion in Endocrine and Metabolic Research 2021;19:52-60. [DOI: 10.1016/j.coemr.2021.06.002] [Reference Citation Analysis]